Clinical trial
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group, Dose Finding Study Evaluating the Safety and Efficacy of Infliximab Administration in Symptomatic Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00056264 is registered in ClinicalTrials.gov with Centocor, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group, Dose Finding Study Evaluating the Safety and Efficacy of Infliximab Administration in Symptomatic Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Lead sponsor
- Centocor, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2002
- Completion date
- December 31, 2004
- Enrollment
- 234 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
chronic obstructive pulmonary disease, copd